Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 5, Issue 8, Pages e1389-e1389
Publisher
Springer Nature
Online
2014-08-28
DOI
10.1038/cddis.2014.346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
- (2013) S Maïga et al. BRITISH JOURNAL OF CANCER
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Vitamin D: Metabolism, molecular mechanisms, and mutations to malignancies
- (2013) Natalie Nemazannikova et al. MOLECULAR CARCINOGENESIS
- The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)
- (2012) Richa Dawar et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Lenalidomide-mediated enhanced translation of C/EBP -p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
- (2012) C. J. Hickey et al. BLOOD
- Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
- (2012) Heather E. Eve et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
- (2012) S. Surget et al. CANCER RESEARCH
- Vitamin D has wide regulatory effects on histone demethylase genes
- (2012) Fábio Pereira et al. CELL CYCLE
- The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement
- (2012) Clifford J. Rosen et al. ENDOCRINE REVIEWS
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network
- (2012) Martin Dreyling et al. LEUKEMIA & LYMPHOMA
- Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications
- (2012) Eleftheria Hatzimichael et al. LEUKEMIA & LYMPHOMA
- The application and biology of immunomodulatory drugs (IMiDs) in cancer
- (2012) Beiqing Pan et al. PHARMACOLOGY & THERAPEUTICS
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics
- (2011) Carole Brosseau et al. APOPTOSIS
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
- (2011) Asher A. Chanan-Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- DNA hypermethylation as a chemotherapy target
- (2011) Juan Ren et al. CELLULAR SIGNALLING
- ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents
- (2011) Cyrille Touzeau et al. CLINICAL CANCER RESEARCH
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
- (2011) Omar Khan et al. IMMUNOLOGY AND CELL BIOLOGY
- DNA Methylation and Demethylation in Mammals
- (2011) Zhao-xia Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vitamin D and Prevention of Cancer — Ready for Prime Time?
- (2011) JoAnn E. Manson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Younger Patients With Mantle Cell Lymphoma
- (2011) Stéphanie Harel et al. SEMINARS IN HEMATOLOGY
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
- (2010) L Bodet et al. BRITISH JOURNAL OF CANCER
- BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak
- (2010) Han Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
- (2010) Matthew T. Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers
- (2010) William B. Grant JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- PAR bZIP-bik is a novel transcriptional pathway that mediates oxidative stress-induced apoptosis in fibroblasts
- (2009) A Ritchie et al. CELL DEATH AND DIFFERENTIATION
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
- (2008) Yuhong Zhou et al. CANCER
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started